Holen Sie sich die Stockscreener-App
70.53
0.08%
-0.06
Schlusskurs vom Vortag:
$70.59
Offen:
$70.79
24-Stunden-Volumen:
332.68K
Relative Volume:
0.23
Marktkapitalisierung:
$12.62B
Einnahmen:
$342.96M
Nettoeinkommen (Verlust:
$-864.29M
KGV:
-13.38
EPS:
-5.27
Netto-Cashflow:
$-636.03M
1W Leistung:
-4.50%
1M Leistung:
-3.58%
6M Leistung:
+3.07%
1J Leistung:
+134.79%
1-Tages-Spanne:
$69.81
$70.82
1-Wochen-Bereich:
$68.67
$74.49
52-Wochen-Spanne:
$21.92
$80.53
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
70.53 | 12.62B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Is Insmed Incorporated (INSM) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Principal Financial Group Inc. Acquires 214,130 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells 18,750 Shares of Stock - MarketBeat
Insmed CEO William Lewis sells $1.79 million in stock By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells $1.79 million in stock - Investing.com
Insmed's SWOT analysis: biopharmaceutical firm's stock poised for growth amid challenges - Investing.com
Tidal Investments LLC Buys 19,696 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Geode Capital Management LLC Purchases 172,664 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed CEO William Lewis sells $1.87 million in stock - Investing.com India
Insmed CEO William Lewis sells $1.87 million in stock By Investing.com - Investing.com Australia
Pulmonary Arterial Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Insmed Inc, Chugai Pharma, Merck Sharp & Dohme, Janssen Pharma, Aerovate - The Globe and Mail
Analysts Set Insmed Incorporated (NASDAQ:INSM) PT at $83.67 - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Position Increased by Orion Portfolio Solutions LLC - MarketBeat
Insmed's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed's SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Wellington Management Group LLP Purchases 24,025 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Should You Invest in Insmed Incorporated (INSM)? - Insider Monkey
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Castleark Management LLC - MarketBeat
Two Sigma Advisers LP Purchases 97,300 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed To Present at December 2024 Investor Conferences - Citizentribune
Soros Fund Management LLC Buys 7,901 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Point72 Asset Management L.P. Sells 5,552,949 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Readystate Asset Management LP Reduces Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
RTW Investments LP Decreases Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
INSM (Insmed) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Parkman Healthcare Partners LLC Has $2.59 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Patient Square Capital LP Makes New $12.53 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Bamco Inc. NY Takes Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Cerity Partners LLC Buys 17,869 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Stake Reduced by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Sells 114,851 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Erste Asset Management GmbH Buys New Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Why Is Insmed Incorporated (INSM) Among the Best High Growth Healthcare Stocks to Invest In Now? - Insider Monkey
Insmed to Present at Evercore ISI HealthCONx and Nasdaq Investor Conferences - StockTitan
Bellevue Group AG Reduces Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Eventide Asset Management LLC Grows Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Vestal Point Capital LP Purchases 850,000 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) is Suvretta Capital Management LLC's 3rd Largest Position - MarketBeat
Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report - GlobeNewswire Inc.
Insmed Incorporated (NASDAQ:INSM) Shares Bought by Ally Bridge Group NY LLC - MarketBeat
Insmed Incorporated (NASDAQ:INSM) is Acuta Capital Partners LLC's 4th Largest Position - MarketBeat
Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy - Simply Wall St
Charles Schwab Investment Management Inc. Raises Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Qsemble Capital Management LP Takes $1.69 Million Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Natixis Advisors LLC Makes New $1.53 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Dec 19 '24 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Dec 19 '24 |
Sale |
69.91 |
18,750 |
1,310,799 |
384,960 |
| Lewis William | Chair and CEO |
Dec 19 '24 |
Sale |
69.92 |
6,830 |
477,550 |
233,924 |
0.10%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):